Journal: BMC Cancer

Article Title: Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells

doi: 10.1186/s12885-019-5713-2

Figure Lengend Snippet: The c-Met inhibitor PF enhanced TRAIL-mediated apoptosis in liposarcoma. PF enhances TRAIL-mediated apoptosis in DDLPS cell lines and PDCs. Shown are the cell viabilities of the established cell lines ( a ) LPS224 and LPS246 and the PDCs ( b ) 11GS-013 and 11GS-079 after 48 h of incubation with 5 μM PF and 5 ng/ml rhTRAIL under the following treatment schemes: negative control, PF alone for 48 h; rhTRAIL alone for 48 h; PF for 24 h followed by rhTRAIL for 24 h; rhTRAIL for 24 h followed by PF for 24 h; and concurrent treatment with PF and rhTRAIL for 48 h. We analyzed apoptosis using annexin V and 7-AAD ( c and d )

Article Snippet: Human recombinant TRAIL protein (rhTRAIL) was purchased from R&D Systems (R&D Systems, Minneapolis, MN, USA). c-Met inhibitors (PHA665752: PHA; PF02341066:crizotinib: PF) were bought from Sellekchem (Houston, TX, USA).

Techniques: Incubation, Negative Control

Journal: BMC Cancer

Article Title: Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells

doi: 10.1186/s12885-019-5713-2

Figure Lengend Snippet: Efficacy of treatment with rhTRAIL in sarcoma cell lines. Cell viability of ADMSCs ( a ), MFH-ino ( b ), SW872 ( c ), and HT1080 ( d ) after 48 h of incubation with serial dilutions of rhTRAIL protein (0–10 ng/ml)

Article Snippet: Human recombinant TRAIL protein (rhTRAIL) was purchased from R&D Systems (R&D Systems, Minneapolis, MN, USA). c-Met inhibitors (PHA665752: PHA; PF02341066:crizotinib: PF) were bought from Sellekchem (Houston, TX, USA).

Techniques: Incubation

Journal: BMC Cancer

Article Title: Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells

doi: 10.1186/s12885-019-5713-2

Figure Lengend Snippet: Efficacy of tumor cell suppression through combined treatment with the c-Met inhibitor PF and rhTRAIL in DDLPS PDCs. Combination treatment with PF and rhTRAIL suppressed cell viability effectively in the DDLPS established cell lines: LPS246 ( a ) and LPS224 ( b ); and in the DDLPS PDCs: 11GS-013 ( c ), 11GS-079 ( d ), 11GS-099 ( e ), 11GS-106 ( f ), 14GS-026 ( g ), and 14GS-076 ( h )

Article Snippet: Human recombinant TRAIL protein (rhTRAIL) was purchased from R&D Systems (R&D Systems, Minneapolis, MN, USA). c-Met inhibitors (PHA665752: PHA; PF02341066:crizotinib: PF) were bought from Sellekchem (Houston, TX, USA).

Techniques:

Journal: Cancer Gene Therapy

Article Title: Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors

doi: 10.1038/s41417-018-0062-x

Figure Lengend Snippet: GBM target cells characterization. a Representative histograms showing GD2 expression, dark gray curve, on human T98G (97 ± 1%), U87MG (57 ± 13%), and A172 (2 ± 1%) GBM cell lines by FACS. APC-conjugated secondary Ab was used as isotype and represented by light gray line. b Expression of both agonistic (DR4 and DR5) and decoy (DcR1, DcR2) TRAIL receptors on GBM cell lines by FACS. c Sensitivity of GBM tumor cells to apoptosis induced by recombinant human TRAIL (rhTRAIL). T98G cell viability by supravital propidium iodide (PI) staining, U87MG and A172 cell viability by MTS assay after 24 h of rhTRAIL treatment at different doses in comparison with untreated control (CTR). p < .05 by Student’s t test between the highest rhTRAIL dose (1000 ng/ml) and untreated CTR, for all GBM lines. Data are expressed as mean ± SD

Article Snippet: After 12 h, different concentrations (10 ng, 50 ng, 100 ng, 500 ng, and 1000 ng/ml) of recombinant human TRAIL (rhTRAIL) (Peprotech, London, UK) were added in the culture media.

Techniques: Expressing, Recombinant, Staining, MTS Assay, Comparison, Control

Journal: Cancer Gene Therapy

Article Title: Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors

doi: 10.1038/s41417-018-0062-x

Figure Lengend Snippet: Bi-functional MSCs exert in vitro cytotoxicity on target GBM cell lines. a In vitro impact of bi-functional MSCs against a T98G, b U87MG, c A172 GBM lines, and d primary C3c GBM cells testing multiple target-to-effector ratios (1:1, 1:2, and 1:5). Tumor cell death by supravital propidium iodide (PI) for T98G, A172, and C3c and by Annexin V/PI staining for U87MG after 24 h (left column) and 48 h (right column). Recombinant human TRAIL (rhTRAIL, 1μg/ml) was used as a positive control of cell death, while tumor cell lines alone as a negative control (CTR). Reported p values regard multiple comparisons among mTRAIL MSCs and bi-functional MSC conditions versus control groups represented by EV MSCs, GD2 tCAR MSCs, rhTRAIL, or CTR. For T98G, * p < .05, ° p < .01, § p < .01; for U87MG, * p < .05, ° p < .05, § p < .05; for A172, * p < .05, ° p < .01, § p < .05; for C3c, * p < .05, ° p < .001, § p < .00. All p values have been calculated by Student’s t test. Data are expressed as mean ± SD

Article Snippet: After 12 h, different concentrations (10 ng, 50 ng, 100 ng, 500 ng, and 1000 ng/ml) of recombinant human TRAIL (rhTRAIL) (Peprotech, London, UK) were added in the culture media.

Techniques: Functional Assay, In Vitro, Staining, Recombinant, Positive Control, Negative Control, Control

Journal: BMC Cancer

Article Title: The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells

doi: 10.1186/s12885-018-4352-3

Figure Lengend Snippet: ILz:rhTRAIL showed the highest cell death inducing ability in TRAIL susceptible cells. Indicated cells were cultured onto a 96-well plate and treated with varying recombinant TRAIL proteins: rmT, recombinant mouse TRAIL from Peprotech (rmTRAIL); rhT, recombinant human TRAIL from Peprotech (rhTRAIL); ILz:T, isoleucine zipper hexamerization motif containing recombinant human TRAIL. ( a ) HeLa, CT26, and B16F10 cells were treated with varying recombinant TRAIL proteins (100 ng/ml). After 16 h, cell survival was examined by XTT assay. ( b ) Three human cell lines (Jurkat, MDA-MB-231, and HEK 293) and two murine cell lines (BMK and 4 T1) were treated with varying recombinant TRAIL proteins (100 ng/ml). To investigate TRAIL-susceptibility, cell death was analyzed by XTT assay 24 h after treatment. The relative values of the XTT assay were examined after comparing the results to untreated controls. * p < 0.05, compared with untreated controls by Student’s t -test

Article Snippet: Recombinant human and mouse TRAIL proteins (rhTRAIL and rmTRAIL) were purchased from PeproTech (PeproTech Korea, Seoul, South Korea): rhTRAIL (310–04); rmTRAIL (315–19).

Techniques: Cell Culture, Recombinant, XTT Assay

Journal: BMC Cancer

Article Title: The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells

doi: 10.1186/s12885-018-4352-3

Figure Lengend Snippet: ILz:rhTRAIL showed the highest cell death inducing ability in the combination treatment of recombinant TRAIL and bortezomib. Cells were cultured onto 96-well plates with 80% to 90% of confluency. Cell death rates were analyzed by XTT assay 24 h after the indicated treatment. The relative values of the XTT assay were examined following comparison to untreated controls. ( a ) Each cell was treated with 100 ng/ml of recombinant TRAIL protein and a distinctive amount of bortezomib as indicated: rmT, recombinant mouse TRAIL from Peprotech (rmTRAIL); rhT, recombinant human TRAIL from Peprotech (rhTRAIL); ILz:T, isoleucine zipper hexamerization motif containing recombinant human TRAIL (ILz:rhTRAIL). ( b ) Two TRAIL-resistant cell lines (B16F10 and CT26) were treated with fixed amounts of bortezomib (50 and 100 nM) and serially increasing amounts of ILz:rhTRAIL. ( c ) Two TRAIL-sensitive cell lines (HEK 293 and MDA-MB-231) were treated with fixed amounts of bortezomib (25 and 50 nM) and serially increasing amounts of ILz:rhTRAIL: bort, bortezomib. * and ** p < 0.05 and p < 0.1 by Student’s t -test, respectively

Article Snippet: Recombinant human and mouse TRAIL proteins (rhTRAIL and rmTRAIL) were purchased from PeproTech (PeproTech Korea, Seoul, South Korea): rhTRAIL (310–04); rmTRAIL (315–19).

Techniques: Recombinant, Cell Culture, XTT Assay, Comparison

Journal: BMC Cancer

Article Title: The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells

doi: 10.1186/s12885-018-4352-3

Figure Lengend Snippet: Combined treatment-induced cell death was inhibited by anti-TRAIL antibody and pan-caspase inhibitor. ( a ) After the pre-treatment of anti-TRAIL antibody (1 μg/ml) for 1 h, B16F10 and CT26 cells were treated with the indicated amount of bortezomib (50 nM) and varying amounts of ILz:rhTRAIL: ILz:T, ILz:rhTRAIL; bort, bortezomib; anti-T, anti-TRAIL antibody. Cell death was analyzed by XTT assay 24 h after treatment. ( b ) B16F10 and CT26 cells were cultured onto a 96-well plate and treated with ILz:rhTRAIL (100 ng/ml) and bortezomib (100 nM) with or without z-VAD-fmk (50 μM) pre-treatment for 1 h. After 24 h, cell death was assayed by XTT: ILz:T, ILz:rhTRAIL; bort, bortezomib; z-VAD, z-VAD-fmk. * p < 0.05 by Student’s t -test. ( c ) B16F10 cells were stained with propidium iodide (PI) and Annexin V using FITC Annexin V Apoptosis Detection Kit (BD Biosciences). Cells were harvested after trypsin treatment and the stained populations were analyzed by Flow cytometry (FACSCalibur™, BD Biosciences, US) using BD CellQuest™ program. The populations (%) are marked in the figures

Article Snippet: Recombinant human and mouse TRAIL proteins (rhTRAIL and rmTRAIL) were purchased from PeproTech (PeproTech Korea, Seoul, South Korea): rhTRAIL (310–04); rmTRAIL (315–19).

Techniques: XTT Assay, Cell Culture, Staining, Flow Cytometry